MNG7
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.279
- INTERFERON_ALPHA_RESPONSE+0.250
- MYOGENESIS+0.248
- COAGULATION+0.245
- INTERFERON_GAMMA_RESPONSE+0.244
- INFLAMMATORY_RESPONSE+0.243
- IL2_STAT5_SIGNALING+0.239
- ANGIOGENESIS+0.212
- PANCREAS_BETA_CELLS+0.194
- KRAS_SIGNALING_DN+0.172
Top 10 suppressed
- G2M_CHECKPOINT-0.474
- E2F_TARGETS-0.470
- PROTEIN_SECRETION-0.355
- UNFOLDED_PROTEIN_RESPONSE-0.342
- MTORC1_SIGNALING-0.331
- MITOTIC_SPINDLE-0.321
- MYC_TARGETS_V1-0.314
- MYC_TARGETS_V2-0.259
- PI3K_AKT_MTOR_SIGNALING-0.178
- GLYCOLYSIS-0.163
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-38-A44F-01A-11R-A24H-07 | — | cohortA1 | 0.902 |
| 2 | TCGA-E9-A5FK-01A-11R-A27Q-07 | — | B | 0.902 |
| 3 | TCGA-A2-A0CR-01A-11R-A22K-07 | — | B | 0.898 |
| 4 | 2d8d97e6-b599-4444-8e11-73adb55be0be | — | — | 0.895 |
| 5 | TCGA-85-A513-01A-12R-A26W-07 | — | cohortA1 | 0.889 |
| 6 | TCGA-55-7728-01A-11R-2187-07 | — | cohortA1 | 0.883 |
| 7 | MDT-AP-1164 | Med | Medulloblastoma | 0.880 |
| 8 | TCGA-L4-A4E6-01A-11R-A24H-07 | — | cohortA1 | 0.876 |
| 9 | TCGA-49-4505-01A-01R-1206-07 | — | cohortA1 | 0.875 |
| 10 | TCGA-FD-A43S-01A-21R-A23W-07 | — | — | 0.874 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.279 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.250 | Inavolisib | — uncovered |
| MYOGENESIS | 0.248 | Inavolisib | — uncovered |
| COAGULATION | 0.245 | Binimetinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.244 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.243 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.239 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.212 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.194 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.172 | Remibrutinib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.170 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.164 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.115 | Inavolisib | — uncovered |
| COMPLEMENT | 0.115 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.087 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.075 | Idelalisib | — uncovered |
| HYPOXIA | 0.051 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.034 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.031 | Temsirolimus | — uncovered |